摘要:
BACKGROUND: The prevalence of heart failure is increasing yearly. Although traditional treatment methods have made great progress in alleviating the progression of heart failure, cardiac tissue injury cannot be thoroughly cured. Cell therapy, however, has the potential to completely cure it through myocardial regeneration. OBJECTIVE: To review the current progress in adult stem cells from different sources in the treatment of heart failure. METHODS: A computer-based retrieval of PubMed and CNKI databases was performed in order to search relevant articles published from 2001 till now, using the keywords of "heart failure, adult stem cells, skeletal myoblasts, cardiac stem cells, mesenchymal stem cells. After removal of repetitive or irrelevant articles, 61 articles were finally reviewed. RESULTS AND CONCLUSION: Currently used adult stem cells for treating heart failure mainly include skeletal myoblasts, bone marrow mesenchymal stem cells, adipose-derived mesenchymal stem cells, human umbilical cord blood mesenchymal stem cells and cardiac stem cells. Most clinical results have shown that adult stem cells have a good effect in the treatment of heart failure, and cause few adverse reactions. The mechanism of adult stem cells in the treatment of heart failure may be related to post-transplantation angiogenesis, paracrine mechanisms, and cell fusion, but the choices of specific cell lines, dose, route of administration and treatment frequency as well as the precise mechanism of action still need further studies.%背景:近年来心力衰竭的发病率正在逐年增加,尽管传统治疗手段已取得了巨大的进步,但只能起到延缓心力衰竭进程的作用,并不能彻底解决心脏组织损伤的根本问题.而细胞治疗具有改变心力衰竭治疗现状的潜力,可以通过心肌再生彻底根治心力衰竭.目的:对目前几种不同成体干细胞治疗心力衰竭的研究进展做一综述.方法:以"heart failure,adult stem cells,keletal myoblasts,cardiac stem cells,mesenchymal stem cells"等为关键词检索PubMed等外文数据库,以"心力衰竭、成体干细胞、骨骼肌成肌细胞、心脏干细胞、间充质干细胞"等关键词检索CNKI等中文数据库从2001年至今的相关文献,排除与文章研究目的无关及重复性文章,纳入符合标准的61篇文献进行综述.结果与结论:目前临床研究用于治疗心力衰竭的成体干细胞种类主要包括骨骼肌成肌细胞、骨髓间充质干细胞、脂肪间充质干细胞、人脐血间充质干细胞、心脏干细胞.多数临床结果显示成体干细胞在治疗心力衰竭上具有良好的效果且不良反应小,成体干细胞治疗心力衰竭的作用机制可能与移植形成新的血管、旁分泌机制、细胞融合有关,但具体细胞株、剂量、给药途径、治疗频率的选择以及精确的作用机制等仍需进一步研究.